Back to News
Market Impact: 0.2
Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AHA Hypertension
Source: GlobeNewswire
Healthcare & Biotech
New analyses reported substantial antihypertensive efficacy for aprocitentan in patients with obesity and across the cardiovascular-kidney-metabolic (CKM) continuum. The article excerpt provides no numerical efficacy estimates or additional study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- Up 57% since June: this AI-picked pharma stock keeps climbing
- Why is NeoGenomics stock sliding today?
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- These stocks could benefit from a midterm election shake-up, JPMorgan says
- NeoGenomics stock falls on CEO transition announcement